for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abbott Laboratories

ABT.N

Latest Trade

100.97USD

Change

1.91(+1.93%)

Volume

172,911

Today's Range

99.32

 - 

101.10

52 Week Range

61.62

 - 

102.89

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Abbott Receives FDA Approval For Ios-Compatible App Allowing People Living With Chronic Pain And Movement Disorders To Personalize Therapy Via Their Mobile Device

July 23 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT RECEIVES FDA APPROVAL FOR IOS-COMPATIBLE APP ALLOWING PEOPLE LIVING WITH CHRONIC PAIN AND MOVEMENT DISORDERS TO PERSONALIZE THERAPY VIA THEIR MOBILE DEVICE.ABBOTT - APPLE‡ SMARTPHONE-COMPATIBLE DIGITAL HEALTH TOOL FITS WITHIN COMPANY'S BROADER NEUROSPHERE DIGITAL CARE CONNECTED CARE MANAGEMENT PLATFORM.ABBOTT LABORATORIES - PATIENT CONTROLLER APP WITH PERSONALIZED ACCESS TO THERAPY WILL BE MADE AVAILABLE STARTING IN COMING WEEKS.

Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call

July 16 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT CEO SAYS AT THE END OF JUNE, PROCEDURE VOLUMES REBOUNDED TO 90% OF PRE-CRISIS LEVELS ON AVERAGE IN U.S. - CONF CALL.ABBOTT CEO SAYS WILL LAUNCH FREESTYLE LIBRE 2 IN THE NEXT FEW WEEKS AT THE SAME PRICE AS THE CURRENT AVAILABLE FREESTYLE LIBRE 14-DAY SYSTEM - CONF CALL.ABBOTT CEO SAYS TESTING VOLUMES IN DIAGNOSTIC BUSINESS EXCLUDING COVID-19 TESTS, REBOUNDED TO ABOUT 90% OF PRE-COVID LEVELS BY END OF Q2 - CONF CALL.ABBOTT IN ADDITION TO MOLECULAR TESTING, ANTICIPATE INCREASED DEMAND FOR OTHER TYPES OF TESTS, INCLUDING BOTH ANTIGEN AND ANTIBODY - CONF CALL.ABBOTT CEO SAYS " IT'S CLEAR THAT THE NEED FOR TESTING IS LARGE AND IT ISN'T GOING AWAY" - CONF CALL.ABBOTT CEO SAYS AS VACCINES BECOME AVAILABLE, ANTICIPATE CONTINUED SURVEILLANCE TESTING TO MONITOR AND ASSESS FOR BOTH NATURAL AND VACCINE-RELATED IMMUNE RESPONSE - CONF CALL.ABBOTT CEO SAYS THE CAPACITY WE ARE BUILDING FOR COVID-19 TESTING IS NOT ONLY FOR A HIGH DEMAND DURING THE NEXT 12-24 MONTHS - CONF CALL.

Abbott Reports Second-Quarter Earnings Per Share $0.30 From Continuing Operations

July 16 (Reuters) - Abbott Laboratories <ABT.N>::REPORTS SECOND-QUARTER 2020 RESULTS, EXCEEDS ANALYSTS' EXPECTATIONS.SEES FY 2020 ADJUSTED EARNINGS PER SHARE AT LEAST $3.25 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2020 GAAP EARNINGS PER SHARE AT LEAST $2.00 FROM CONTINUING OPERATIONS.Q2 ADJUSTED EARNINGS PER SHARE $0.57 FROM CONTINUING OPERATIONS.Q2 GAAP EARNINGS PER SHARE $0.30 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.41 -- REFINITIV IBES DATA.LABORATORIES - PROJECTS FULL-YEAR 2020 DILUTED EPS FROM CONTINUING OPERATIONS ON A GAAP BASIS OF AT LEAST $2.00.LABORATORIES - SEES FULL-YEAR ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS OF AT LEAST $3.25.LABORATORIES - Q2 WORLDWIDE SALES OF $7.3 BILLION DOWN 8.2% ON REPORTED BASIS & 5.4% ON ORGANIC BASIS, WHICH EXCLUDES IMPACT OF FOREIGN EXCHANGE.LABORATORIES - QUARTERLY MEDICAL DEVICES SALES $2.42 BILLION, DOWN 21.2% ON REPORTED BASIS.IN CORE LABORATORY DIAGNOSTICS, LOWER ROUTINE DIAGNOSTICS TESTING PARTIALLY OFFSET BY SALES OF COVID-19 LABORATORY-BASED TESTS FOR DETECTION OF IGG ANTIBODY IN QUARTER.LABORATORIES QTRLY DIAGNOSTICS SALES $1.99 BILLION, UP 4.7% ON A REPORTED BASIS.LABORATORIES - SAW SIGNIFICANT IMPROVEMENTS IN GROWTH TRENDS THROUGHOUT QUARTER IN BUSINESS AREAS THAT WERE INITIALLY MOST IMPACTED BY PANDEMIC.

Abbott Receives FDA Approval For Heart Rhythm Devices With Bluetooth Connectivity, Continuous Remote Monitoring

July 6 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT RECEIVES FDA APPROVAL FOR NEW HEART RHYTHM DEVICES FEATURING BLUETOOTH CONNECTIVITY AND CONTINUOUS REMOTE MONITORING.

FDA Says Request To Update Instructions For Use Of Abbott's Sars-CoV-2 IgG Assay Run On Architect I & Alinity I Systems Is Granted

June 23 (Reuters) - U.S. FDA::FDA IN LETTER DATED JUNE 22 SAYS REQUEST TO UPDATE INSTRUCTIONS FOR USE OF ABBOTT'S SARS-COV-2 IGG ASSAY RUN ON ARCHITECT I & ALINITY I SYSTEMS IS GRANTED.

Abbott Laboratories Files For Potential 2-Part, Notes Offering

June 22 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT LABORATORIES FILES FOR POTENTIAL 2-PART, NOTES OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Abbott Laboratories Files For Potential Debt Shelf Offering

June 22 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.

Abbott's Freestyle Libre 2 Cleared In U.S. For Adults And Children With Diabetes

June 15 (Reuters) - Abbott Laboratories <ABT.N>::ABBOTT'S FREESTYLE® LIBRE 2 ICGM CLEARED IN U.S. FOR ADULTS AND CHILDREN WITH DIABETES, ACHIEVING HIGHEST LEVEL OF ACCURACY AND PERFORMANCE STANDARDS.ABBOTT LABORATORIES - WILL OFFER NEW SYSTEM AT SAME PRICE AS CURRENTLY AVAILABLE FREESTYLE LIBRE 14 DAY SYSTEM.ABBOTT- FREESTYLE LIBRE 2 SYSTEM WILL BE AVAILABLE IN COMING WEEKS AT PARTICIPATING PHARMACIES AND DURABLE MEDICAL EQUIPMENT SUPPLIERS ACROSS U.S..ABBOTT - FREESTYLE LIBRE 2 SYSTEM TO BE AVAILABLE IN COMING WEEKS AT PARTICIPATING PHARMACIES, DURABLE MEDICAL EQUIPMENT SUPPLIERS ACROSS U.S..

Abbott Declares Quarterly Dividend

June 12 (Reuters) - Abbott Laboratories <ABT.N>::DECLARES 386TH CONSECUTIVE QUARTERLY DIVIDEND.SETS QUARTERLY DIVIDEND OF $0.36PER SHARE.

Bigfoot Biomedical® Closes Series C Financing With $55 Million As Company Readies For FDA Submission Of Bigfoot Unity

June 2 (Reuters) - BIGFOOT BIOMEDICAL, INC :BIGFOOT BIOMEDICAL® CLOSES SERIES C FINANCING WITH $55 MILLION AS COMPANY READIES FOR FDA SUBMISSION OF BIGFOOT UNITY.BIGFOOT BIOMEDICAL, INC - ROUND WAS LED BY ABBOTT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up